NICO - a national prospective non-interventional Study (NIS) with Nivolumab as Monotherapy or in combination with Ipilimumab in Patients with advanced (inoperable or metastatic) Melanoma to collect real-world data

被引:0
|
作者
Gutzmer, R. [1 ]
Eigentler, T. [2 ]
Mohr, P. [3 ]
Becker, S. [4 ]
Haferkamp, S. [5 ]
Meiss, F. [6 ]
Pfoehler, C. [4 ]
Satzger, I. [7 ]
Schneider, S. W. [8 ]
Terheyden, P. [9 ]
Ulrich, J. [10 ]
Utikal, J. [11 ]
Weichenthal, M. [12 ]
Weishaupt, C. [13 ]
Zimmer, L. [14 ]
Schadendorf, D. [14 ]
机构
[1] Hannover Med Sch, Klin Dermatol Allergol & Venerol, Haut Tumor Zentrum, Hannover, Germany
[2] Eberhard Karls Univ Tubingen, Tubingen, Germany
[3] Elbe Kliniken Buxtehude, Buxtehude, Germany
[4] Univ Klinikum Saarlandes, Homburg, Germany
[5] Univ Klinikum Regensburg, Regensburg, Germany
[6] Univ Klinikum Freiburg, Freiburg, Germany
[7] Hannover Med Sch, Hannover, Germany
[8] Univ Klinikum Hamburg Eppendorf UKE, Hamburg, Germany
[9] Univ Klinikum Schleswig Holstein, Lubeck, Germany
[10] Harzklinikum Dorothea Christiane Erxleben GmbH, Quedlinburg, Germany
[11] Univ Klinikum Mannheim, Mannheim, Germany
[12] Univ Klinikum Schleswig Holstein, Kiel, Germany
[13] Univ Klinikum Munster, Munster, Germany
[14] Univ Klinikum Essen, Essen, Germany
来源
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT | 2018年 / 16卷
关键词
D O I
暂无
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
P131
引用
收藏
页码:79 / 79
页数:1
相关论文
共 50 条
  • [1] Real-world evidence in melanoma: A national, prospective, non-interventional study (NIS) of nivolumab monotherapy or in combination with ipilimumab in patients with advanced (unresected or metastatic) melanoma (NICO)
    Eigentler, T.
    Gutzmer, R.
    Mohr, P.
    Kaatz, M.
    Pfohler, C.
    Terheyden, P.
    Ulrich, J.
    Utikal, J.
    Zimmer, L.
    Schadendorf, D.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 159 - 159
  • [2] Real-world Data on advanced Melanoma: First Data from a national, prospective, non-interventional Study of Nivolumab in Combination with Ipilimumab or as Nivolumab Monotherapy (NICO)
    Weichenthal, M.
    Gutzmer, R.
    Eigentler, T.
    Mohr, P.
    Goeppner, D.
    Haferkamp, S.
    Herber, M.
    Herbst, R.
    Meier, F.
    Meiss, F.
    Pfoehler, C.
    Schneider, S. W.
    Terheyden, P.
    Ulrich, J.
    Utikal, J.
    Weishaupt, C.
    Welzel, J.
    Schadendorf, D.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2019, 17 : 5 - 6
  • [3] Nico: Real World Evidence in Advanced Melanoma; A National Prospective Non-Interventional Study of Nivolumab Monotherapy or in Combination with Ipilimumab in Patients with Advanced Melanoma and in Patients with Adjuvant Nivolumab Therapy
    Schadendorf, Dirk
    Eigertler, Thomas
    Mohr, Peter
    Weichenthal, Michael
    Goeppner, Daniela
    Haferkamp, Sebastian
    Herber, Martin
    Meier, Friedegund
    Meiss, Frank
    Pfoehler, Claudia
    Schneider, Stefan W.
    Terheyden, Patrick
    Ulrich, Lens
    Utikal, Jochen
    Weishaupt, Carsten
    Gutzmer, Ralf
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 175 - 175
  • [4] Real World Data on the Use of Nivolumab (Nivo) as Monotherapy or in Combination with Ipilimumab (Nivo plus Ipi) in the Treatment of advanced Melanoma: Interim Results of the non-interventional Study NICO
    Ugurel, S.
    Satzger, I.
    Eigentler, T.
    Mohr, P.
    Goeppner, D.
    Herber, M.
    Herbst, R.
    Kaehler, K. C.
    Meier, F.
    Meiss, F.
    Pfoehler, C.
    Sachse, M. M.
    Schneider, S. W.
    Terheyden, P.
    Ulrich, J.
    Utikal, J. S.
    Welzel, J.
    Schadendorf, D.
    Gutzmer, R.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2020, 18 : 69 - 70
  • [5] Nivolumab (NIVO) monotherapy or combination therapy with ipilimumab (NIVO plus IPI) in advanced melanoma patients with brain metastases: Real-world evidence from the German non-interventional study NICO
    Gutzmer, R.
    Eigentler, T.
    Mohr, P.
    Weichenthal, M.
    Duecker, P.
    Gebhardt, C.
    Goeppner, D.
    Haferkamp, S.
    Kaehler, K.
    Meier, F.
    Pfoehler, C.
    Satzger, I.
    Sickmann, T.
    Sindrilaru, A.
    Terheyden, P.
    Ugurel, S.
    Ulrich, J.
    Utikal, J.
    Weishaupt, C.
    Schadendorf, D.
    ANNALS OF ONCOLOGY, 2020, 31 : S746 - S747
  • [6] Use of nivolumab (NIVO) in adjuvant melanoma patients: real world data from NICO, a national prospective non-interventional study
    Gutzmer, Ralf
    Mohr, Peter
    Eigentler, Thomas
    Grimmelmann, Imke
    Zimmer, Lisa
    Livingstone, Elisabeth
    Ugurel, Selma
    Utikal, Jochen
    Mueller, Verena
    Goeppner, Daniela
    Herbst, Rudolf
    Kreuter, Alexander
    Pfoehler, Claudia
    Hollburg, Wiebke
    Carmen, Loquai
    Herber, Martin
    Kaehler, Katharina C.
    Weichenthal, Michael
    Schadendorf, Dirk
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 236 - 237
  • [7] Age-dependent Efficacy and Safety of Nivolumab (NIVO) as Monotherapy or Combination Therapy with Ipilimumab (NIVO plus IPI) in Patients with advanced Melanoma in the non-interventional Study (NIS) NICO
    Schadendorf, D.
    Ugurel, S.
    Eigentler, T.
    Mohr, P.
    Wei-Chenthal, M.
    Gebhardt, C.
    Goppner, D.
    Haferkamp, S.
    Herbst, R.
    Kahler, K.
    Kreuter, A.
    Meier, F.
    Pfohler, C.
    Sachse, M. M.
    Sickmann, T.
    Terheyden, P.
    Ulrich, J.
    Utikal, J. S.
    Grimmel-Mann, I.
    Gutzmer, R.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2021, 19 : 16 - 17
  • [8] Early safety signals from nivolumab in the adjuvant treatment of real-world melanoma patients derived from the German prospective non-interventional study NICO
    Gutzmer, R.
    Weichenthal, M.
    Eigentler, T.
    Grimmelmann, I.
    Sickmann, T.
    Zimmer, L.
    Livingstone, E.
    Ugurel, S.
    Utikal, J. S.
    Muller, V.
    Goppner, D.
    Herbst, R.
    Kreuter, A.
    Pfohler, C.
    Hollburg, W.
    Loquai, C.
    Kahler, K.
    Mohr, P.
    Schadendorf, D.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2022, 20 : 18 - 19
  • [9] Real-world evidence in gastric and esophageal cancer: a non-interventional study of first-line nivolumab plus chemotherapy or in combination with ipilimumab (the NIS INGA study)
    Stein, A.
    Lorenzen, S.
    Herber, M.
    Kisro, J.
    Lordick, F.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 245 - 245
  • [10] Real-world efficacy and safety data of nivolumab and ipilimumab combination therapy in Japanese patients with advanced melanoma
    Takahashi, Akira
    Namikawa, Kenjiro
    Ogata, Dai
    Nakano, Eiji
    Jinnai, Shunichi
    Nakama, Kenta
    Tsutsui, Keita
    Muto, Yusuke
    Mizuta, Haruki
    Yamazaki, Naoya
    JOURNAL OF DERMATOLOGY, 2020, 47 (11): : 1267 - 1275